There is strong evidence at the individual level and the population level that an efficient cytotoxic T lymphocyte (CTL) response to HTLV-1 limits the proviral load and the risk of associated inflammatory diseases such as HAM/TSP. This evidence comes from host population genetics, viral genetics, DNA expression microarrays and assays of lymphocyte function. However, until now there has been no satisfactory and rigorous means to define or to measure the efficiency of an antiviral CTL response. Recently, methods have been developed to quantify lymphocyte turnover rates in vivo and the efficiency of anti-HTLV-1 CTLs ex vivo. Data from these new techniques appear to substantiate the conclusion that variation between individual hosts in the rate at which a single CTL kills HTLV-1-infected lymphocytes is an important determinant, perhaps the decisive determinant, of the proviral load and the risk of HAM/ TSP. With these experimental data, it is becoming possible to refine, parameterize and test mathematical models of the immune control of HTLV-1, which are a necessary part of an understanding of this complex dynamic system.
Introduction
Three broad questions have driven research into the immune response to HTLV-1. First, how does HTLV-1 persist in the individual host? In particular, what is the role of the immune response in controlling or limiting viral persistence? Second, why do some HTLV-1-infected people develop a consequent inflammatory disease such as HAM/TSP, whereas the majority remain asymptomatic carriers of the virus? Is this difference in the outcome of infection due primarily to variation in the host or variation in the virus? Third, how is the inflammatory lesion in HAM/TSP initiated and maintained, and how can the inflammation be halted? In this review, we shall first summarize briefly the progress that has been made in answering each of these questions during the last two decades. We then review the more recent work that is attempting to resolve some of the outstanding issues. We conclude that the efficiency of a person's CTL response to HTLV-1 plays a dominant role in determining the proviral load of HTLV-1 and the risk of the associated inflammatory diseases.
How does HTLV-1 persist in the host?
The apparent absence of HTLV-1 virions, mRNA or protein in circulating PBMCs in the majority of HTLV-1-infected people led to the conclusion that the proviral load of HTLV-1, which may reach more than 30% of peripheral blood mononuclear cells (PBMCs) and more than 50% of CD4 þ cells, is maintained mainly by proliferation of provirus-containing cells (Cavrois et al., 1996; Etoh et al., 1997; Eiraku et al., 1998) , rather than full-cycle virus replication mediated by reverse transcriptase. This conclusion was corroborated by the relative lack of sequence variation in HTLV-1 both within and between isolates (Daenke et al., 1990; Kinoshita et al., 1991; Komurian et al., 1991; Slattery et al., 1999) , which appeared to exclude a major role of the error-prone reverse transcriptase in maintaining the proviral load.
However, in the absence of malignant transformation, continued mitosis of HTLV-1-positive cells must be driven by expression of HTLV-1 genes. Persistent expression of mRNA was detected in a low proportion (B1/5000) of cells in some individuals by RT-PCR (Gessain et al., 1991) , but the importance of such expression remained unclear. The discovery of a chronically activated cytotoxic T lymphocyte (CTL) response to HTLV-1, particularly against the Tax protein (Jacobson et al., 1990; Kannagi et al., 1991; Parker et al., 1992; Goon et al., 2004b) , and a high titre of anti-HTLV-1 antibody, which often includes IgM (Nagasato et al., 1991; Kira et al., 1992; Ishihara et al., 1994) , strongly supported the idea that there was persistent expression of HTLV-1 proteins. Why, then, is HTLV-1 protein expression in fresh PBMCs low or undetectable (Moritoyo et al., 1999; Hanon et al., 2000a) ? An important clue came from the demonstration by Hanon et al. (2000a) that CD4 þ T cells freshly isolated from an HTLV-1-infected person spontaneously express HTLV-1 proteins -initially Tax protein, then Gag. This expression reaches a peak after about 12 h of incubation. Readdition of the CD8 þ T cellswhich include CTLs -from the same blood sample reduced the expression of Tax in a dose-dependent manner (Hanon et al., 2000a) . This observation suggested that efficient surveillance by anti-HTLV-1 CTLs in vivo might suppress the frequency of Taxexpressing cells in the circulation to a level below the limit of detection by flow cytometry (Bangham, 2003) .
The notion that HTLV-1-specific CTLs might play a decisive role in limiting HTLV-1 gene expression (and therefore the proviral load) in vivo was consistent with the finding of Niewiesk et al. (1994) and Niewiesk and Bangham (1996) that the Tax gene of HTLV-1 was subject to positive selection, especially in healthy asymptomatic carriers of the virus. Tax protein is the dominant target of HTLV-1-specific CTLs (Jacobson et al., 1990; Kannagi et al., 1991; Parker et al., 1992; Goon et al., 2004b) , and the only plausible force that has been identified which might exert positive selection on the Tax gene is the strong anti-Tax CTL response. Indeed, naturally occurring sequence variants of HTLV-1 Tax encode epitopes that escape autologous CTL recognition (Niewiesk et al., 1995) , which is consistent with CTL-mediated selection on the Tax gene. Such CTL escape variants of Tax are, however, usually defective in Tax transcriptional activity (Niewiesk et al., 1995) .
The following picture of HTLV-1 persistence has emerged from recent experimental work (Asquith et al., 2000; Overbaugh and Bangham, 2001; Bangham, 2003) . Cells that carry HTLV-1 spontaneously start to transcribe the provirus in vivo; Tax expression drives mitosis of the infected CD4 þ T cells and maintains the proviral load. However, HTLV-1-expressing CD4 þ T cells are usually killed by autologous CTLs before they complete the replication cycle of HTLV-1. A small proportion of infected cells do complete the replication cycle; such cells can infect other T-cells directly through a cell-contact-triggered 'virological synapse' in a remarkable subversion of normal T-cell physiology . Transmission of HTLV-1 via this 'infectious' route may cause the observed preferential infection of T-cells that recognize HTLV-1 antigens (Hanon et al., 2000b; Goon et al., 2004a) . Cells that express CTL escape variants of Tax have a survival advantage, but such cells do not outgrow the cells that express the wild-type Tax sequence because the CTL escape mutations also reduce the efficacy of Tax protein in transactivating the host cell pathways responsible for T-cell proliferation. In this way, an equilibrium is established (Nowak and Bangham, 1996) between the virus, which is persistently attempting to replicate, and the immune (largely CTL) counter-attack. If this picture of a dynamic equilibrium is correct, what are the implications? Here we suggest six such implications, and examine recent evidence for each:
(i) HTLV-1-specific CTLs must be highly active in killing HTLV-1-infected lymphocytes in vivo.
(ii) Individuals with a high frequency of HTLV-1-specific CTLs have a strong anti-HTLV-1 response. (iii) Differences in proviral load -and associated differences in the risk of inflammatory diseases such as HAM/TSP -should be associated with differences between individuals in the efficiency of CTL-mediated surveillance against HTLV-1, that is, in the rate of CTL-mediated lysis of infected cells. (iv) Individual differences in CTL efficacy are likely to be genetically determined, because each person appears to have their own 'set point' of proviral load. Therefore, genetic polymorphisms should be associated with individual differences in proviral load and/or in the risk of inflammatory diseases such as HAM/TSP. (v) HTLV-1-infected T cells should have a short life expectancy in vivo. (vi) In addition to frequent spontaneous onset of Tax transcription, there must also be a certain frequency of suppression of Tax transcription, albeit lower than the rate of onset of Tax transcription (see below).
HTLV-1-specific CTLs must be highly active in vivo
Following the first identification of HTLV-1-specific CTLs (Kannagi et al., 1983 (Kannagi et al., , 1984 , Jacobson et al. (1990) and subsequently Parker et al. (1992 Parker et al. ( , 1994 showed that ex vivo CTLs were active against HTLV-1-infected cells. The specific prediction (Nowak and that CTLs are especially active in individuals with a low proviral load, in whom CTL surveillance is putatively more effective, has recently been confirmed by Vine, Heaps and others . These authors used DNA expression microarrays to study the expression of over 12 000 genes in unstimulated T cells taken ex vivo from HTLV-1 infected subjects and uninfected controls. A single small cluster of genes distinguished individuals with a low proviral load from those with a high load. This cluster contained between 9 and 40 genes ( Figure 1 ) that were highly expressed in CD8 þ cells in individuals with a low proviral load. No other significant gene clusters were found either in CD4 þ cells or CD8 þ cells. Remarkably, this highly expressed gene cluster consisted mainly of genes that encode proteins known to be involved in the effector mechanisms of CTL-mediated lysis, including granzymes, perforin, granulysin and NKG2D. Thus, a high level of expression of lymphocyte lysis-related genes was associated with effective control of proviral load, both in asymptomatic HTLV-1 carriers and patients with HAM/TSP.
A high frequency of HTLV-1-specific CTLs should be associated with efficient suppression of HTLV-1 replication, that is, with a low proviral load which show a zero or a weakly positive correlation between proviral load and the frequency of HTLV-1-specific CTLs (Kubota et al., 2000a, b; Betts et al., 2001; Wodarz et al., 2001) . This positive correlation is largely responsible for the presence of a higher frequency of HTLV-1-specific CTLs in patients with HAM/TSP than in asymptomatic carriers (Elovaara et al., 1993; Greten et al., 1998) , although there may be a slightly higher frequency in HAM/TSP patients at a given proviral load.
However, on closer inspection, the logic of this implication is less clear (Bangham, 2003) . A high proviral load will drive replication and activation of HTLV-1-specific CTLs, by providing a strong antigenic stimulus. However, the increased number and activity of CTLs will then more effectively kill HTLV-1-expressing cells, and thereby suppress HTLV-1 replication and lower the proviral load. In turn, the antigenic stimulus will diminish, and so the frequency and activation of specific CTLs will fall. In this case, neither mathematical models nor -still less -intuition can give a robust and reliable prediction where the equilibrium will be struck between the proviral load and CTL frequency. Only one clear conclusion can be drawn here: the frequency of specific CTLs is not a useful or reliable guide to the efficacy of the CTL response to a persistently replicating pathogen at equilibrium.
Differences between individuals in proviral load and the risk of HAM/TSP should be associated with differences in the efficiency of CTL-mediated surveillance Until recently there has been no means to measure the efficiency of CTL-mediated lysis of virus-infected cells in a natural infection. The chief reason for this is that it has not been possible to obtain and detect both CTLs and autologous target (i.e. virus-infected) cells in or near their natural frequency and state of activation. Recently, however, Asquith et al. (2005) have attempted to resolve this difficulty in HTLV-1 infection, in which both the CTLs and HTLV-1-infected CD4 þ cells are frequently present at a sufficiently high frequency in peripheral blood that they can be enumerated without enrichment. Asquith et al. measured the loss of Tax-expressing CD4 þ cells in freshly isolated PBMCs after overnight incubation with different ratios of autologous CD8 þ cells. Neither cytokines nor any other stimulus were added to the cells. In principle, this approach amounts to a quantification of the assay developed by Hanon et al. (2000a) .
The results (Figure 2a) showed that the per-CD8 þ -cell rate of lysis of Tax-expressing CD4 þ cells not only varied widely between individuals but, most importantly, correlated negatively with the proviral load in vivo, both within asymptomatic HTLV-1 carriers and patients with HAM/TSP. This analysis is not subject to the difficult circular argument noted above in the correlation between CTL frequency and proviral load: the lysis assay developed by Asquith et al. (2005) gives an estimate of the CD8 þ cell lytic efficiency at the level of the single cell, not the population of cells. The finding of a significant negative correlation between the CTL lysis rate and proviral load in vivo gives strong credence to the idea that this in vitro measure reflects a physiologically meaningful activity of the CTLs.
These results indicate that CTLs do indeed reduce the proviral load of HTLV-1 in vivo. However by how much is the load reduced? The impact of CTLs has not been quantified in any natural persistent viral infection. Using the results of the ex vivo lysis assay, we can estimate the proportion of the observed variation between individuals in HTLV-1 proviral load that is explained by the measured variation in CD8 þ cell-mediated lytic rate. Surprisingly, the results show that this proportion lies between 30 and 50% (Asquith et al., 2005) . If this is Venn diagram showing the number of genes that occurred in each CD8L cluster and the number and identity of genes that occurred in two or more CD8L clusters. In the three experiments, 27, 56 and 53% of genes present in the respective CD8L cluster occurred in this cluster in all three experiments: these shared genes are shown in the central white 'core' group (n ¼ 9 genes). In both this core group and the genes (n ¼ 6) shared by two experiments (gene groups B-D), there was a strong predominance of genes that encode proteins that mediate cellular cytotoxicity (granzymes, perforin, granulysin), T-cell Ag recognition (TCRg, CD8a, NKG2D). Of the five remaining probe sets that appeared in the CD8L cluster in two of the three experiments, two (RANTES, NKG7) are also associated with the lytic granule of cytotoxic lymphocytes. Reproduced, by permission of the publisher, from Vine et al. (2004) correct, it appears that the variation in the lytic rate of HTLV-1-specific CD8 þ lymphocytes is the largest single determinant of individual variation in proviral load and, therefore, in the outcome of infection with HTLV-1 (Asquith et al., 2005; Bangham et al., 1996) . Second, if the measured rate of CD8 þ cell-mediated lysis in vitro is taken as an estimate of the rate of lysis in vivo, the data indicate that each HTLV-1-specific CD8 þ T cell kills about five HTLV-1-infected CD4 þ cells per day. Since a single CTL can lyse a target cell in vitro in 10 min before going on to kill another cell, this estimate seems plausible, even conservative. However, because of the high frequency of infected cells and CTLs, these figures imply that about 10 9 HTLV-1-infected cells are killed per day in a typical HTLV-1-infected host. This surprisingly high figure requires corroboration by an independent experimental technique.
Both this study of CTL-mediated lysis and the DNA expression array study noted above show that strong CD8 þ cell lytic activity is associated with a low proviral load in asymptomatic HTLV-1 carriers and in patients with HAM/TSP: see Figure 2b . However, a closer inspection of the results obtained by Asquith et al. (2005) (Figure 2b) reveals that, at a given rate of CD8 þ cell-mediated lysis, the proviral load is systematically higher in patients with HAM/TSP than in asymptomatic carriers. Possible causes of this CTLindependent difference in proviral load include epigenetic factors associated with the HTLV-1 provirus and host differences in the rate of proliferation of HTLV-1-infected CD4 þ T cells.
Host genetic polymorphisms determine the efficacy of an individual's immune response to HTLV-1
This hypothesis was tested in a large collaborative study of candidate gene polymorphisms in a population with endemic HTLV-1 infection in Kagoshima, southern Japan (Nagai et al., 1998; Jeffery et al., 1999 Jeffery et al., , 2000 Vine et al., 2002) . The power of such candidate gene studies is constrained by the choice of candidate genes, whereas the effectiveness of genome-wide searches for genetic determinants is limited by the low statistical power after correction for multiple statistical tests. However, the results of this study were clear. The strongest identified genetic determinant of proviral was the HLA class 1 genotype (Vine et al., 2002) . Specifically, the genes HLA-A*02 and HLA-Cw*08 were independently and significantly associated with a lower proviral load and a lower risk of HAM/TSP (Jeffery et al., 1999 (Jeffery et al., , 2000 . Since the function of class 1 HLA proteins is to present antigenic peptides to CTLs, these results imply that individuals with HLA-A*02 or HLA-Cw*08 mount a particularly efficient CTL response against HTLV-1. These data are therefore consistent with the evidence from the functional assay (Asquith et al., 2005, Figure 2a ) and the DNA expression analysis ; Figure 1 ) that CTL efficacy is an important determinant, perhaps the decisive determinant, of HTLV-1 proviral load and therefore of the risk of inflammatory disease such as HAM/TSP. The significance of the observed protection associated with HLA-A*02 and HLA-Cw*08 in Kagoshima lies less in the actual identity of these particular molecules than in the implication that CTLs play an important role in controlling HTLV-1 load. While the frequency of polymorphic alleles and therefore the strength of their influence on HTLV-1 infection will differ significantly between different populations, it seems highly improbable that the fundamental mechanisms of immune control will differ.
A further analysis by Furukawa et al. (2000) has cast more light on the protective effect given by HLA-A*02. Furukawa et al. showed that a minor sequence variation in HTLV-1 was associated with a significant difference in the prevalence of HAM/TSP in Kagoshima. Interestingly, HLA-A*02 appeared to give protection against only one of the two prevalent sequence variants of HTLV-1, cosmopolitan subtype B, but not against subtype A. Recently, Sabouri et al. (2005) have confirmed the finding that HLA-A*02 appears not to give protection against infection with cosmopolitan þ cell-mediated lysis shows a statistically significant negative correlation with a low proviral load of HTLV-1 in vivo in both asymptomatic HTLV-1 carriers (AC) and patients with HAM/TSP. These results suggest that there is effective control of HTLV-1 replication in vivo by CTLs. Reproduced, by permission of the publisher, from Asquith et al. (2005) . (b) The mean intensity of mRNA expression of genes that encode CTL lysis-associated proteins also varies inversely with the proviral load of HTLV-1 in vivo. The pattern of variation of mRNA expression intensity, both within and between the two groups of subjects, strongly resembles the pattern of variation in the rate of CD8 þ cell-mediated lysis shown in (a). Data on mRNA expression were taken from the DNA microarray study reported by Vine et al. (2004) subtype A in a population in Iran. Borducchi et al. (2003) found that HLA-A*02 is associated with a lower prevalence of HAM/TSP in white subjects in Brazil, but the HTLV-1 genotype was not identified in this study.
In future studies of the influence of genetic polymorphisms on HTLV-1 infection, it will be important to examine the genes whose expression was associated with rapid and effective CD8 þ cell-mediated lysis of HTLV-1-infected cells in the DNA expression microarray study  Figure 1 ).
HTLV-1-infected cells should have a short life span in vivo, if they are indeed rapidly killed by CTLs Until recently, this implication has been difficult to test directly in natural HTLV-1 infection, because of the lack of a safe technique to label lymphocytes in humans. However, a suitable technique has been developed by Macallan et al. (1998 Macallan et al. ( , 2003 , which involves quantifying the incorporation of the non-radioactive isotope deuterium ( 2 H) from glucose into the DNA of newly divided lymphocytes. A study is currently underway using this technique: preliminary results (Asquith et al., unpublished) suggest that the lifespan of Tax þ cells is indeed significantly shorter than that of Tax À cells in vivo. It will be interesting to use similar techniques in patients with the HTLV-1-associated malignancy adult T-cell leukemia (ATL), to examine the lymphocyte dynamics and the impact of the CTL response on the control of the leukemic cell growth both before (Arnulf et al., 2004) and after (Utsunomiya et al., 2001; Harashima et al., 2004) allogeneic bone marrow transplantation.
Tax expression must be suppressed in a proportion of infected cells
As described above, the proviral load of HTLV-1 appears to be maintained, when an equilibrium is established with the immune response, mainly by proliferation of HTLV-1-infected cells. To maintain the infection, these cells must proliferate faster than uninfected cells, because they are subject to CTL killing in vivo (Asquith et al., 2005) ; cell survival might also be impaired by proviral integration into a critical region of the host genome or by direct toxic effects of the virus. Preferential proliferation of HTLV-1-infected cells requires the expression of HTLV-1 proteins, especially Tax. However, if HTLV-1 provirus-positive clones survived in the host only by persistent expression of the Tax protein, there would be a monotonic (one-way) increase in Tax expression over time: after some weeks or months, all infected cells would express Tax. Since this is not observed, it must be the case that either a proportion of cells that express Tax subsequently shut down Tax expression, or one or both daughter cells that arise by Tax-driven mitosis contain HTLV-1 proviruses that are initially silent. Recently, possible molecular mechanisms for such suppression of Tax expression have been identified, including both HTLV-1 factorsRex (Hidaka et al., 1988) , the pX protein p30 II (Nicot et al., 2004) and HBZ (Gaudray et al., 2002) -and host factors -histone deacetylases (Lemasson et al., 2004) and GLI-2/THP (Smith et al., 2001) . In each case, the evidence to date indicates a partial rather than complete reduction in proviral transcription, and the extent of suppression in natural HTLV-1 infection is not yet known. However, even partial suppression can give a significant survival advantage to an HTLV-1-infected cell because the exposure of the cell to immune surveillance, particularly by CTLs, might be delayed or diminished. Impairment of CTL surveillance may similarly allow HTLV-1-transformed leukemic cells to survive and proliferate (Furukawa et al., 2001; Nomura et al., 2004) . It will be important to identify the mechanisms responsible, and to quantify the degree and the rate of this suppression of proviral expression.
Why do a minority of HTLV-1-infected people develop HAM/TSP, while the majority remain healthy asymptomatic carriers?
No unique sequence variant of HTLV-1 has been associated with HAM/TSP (Daenke et al., 1990; Kinoshita et al., 1991; Komurian et al., 1991; Slattery et al., 1999) . There is evidence from southern Japan (Furukawa et al., 2000) of a significantly greater risk of HAM/TSP in people infected with the cosmopolitan subtype A of HTLV-1 than in those with cosmopolitan subtype B. However, this effect of HTLV-1 genotype is small, so the factors that determine the different outcomes of HTLV-1 infection must lie chiefly in the host. Specifically, it was likely that polymorphisms in genes that influence the immune response account for much of the variation in outcome, that is, the risk of HAM/TSP in HTLV-1-infected individuals and the proviral load.
The protective effects of HLA-A*02 and HLA-Cw*08 in HTLV-1 infection in southern Japan (Jeffery et al., 1999 (Jeffery et al., , 2000 Vine et al., 2002) have been described above, where it was pointed out that the likely mechanism of this protection is efficient lysis of HTLV-1-expressing cells by HLA-A2-restricted and Cw08-restricted CTLs. In the same cohort, the host genotype was determined (Vine et al., 2002; Kodama et al., 2004; Sabouri et al., 2004) at over 70 single-nucleotide polymorphisms (SNPs) in over 50 loci outside HLA class 1. Of these, polymorphisms at four loci (TNFA, IL-15, SDF-1 and IL-10) had statistically significant independent effects on the proviral load or the risk of HAM/TSP, or both. The results are shown in Table 1 , in which the contribution of each significant factor to the risk of HAM/TSP was quantified by standard multivariate techniques.
The effect of the protective alleles HLA-A*02 and -Cw*08 in Kagoshima is exerted mainly through a reduction in proviral load. However, there is an additional statistically significant protective effect of each of these two alleles that remains even after the proviral load has been taken into account (Bangham, 2003) . The mechanism of this additional protective effect associated with HLA class 1 alleles is unknown. The odds ratios for HLA-B*54, IL-15 +191C and IL-10 À592A are calculated in single-factor analyses, not from logistic regression, since the effect of each allele appears to be exerted through an effect on the proviral load of HTLV-1. b A simple odds ratio cannot be calculated for the TNF-a allele, because its effect is exerted through a strong interaction with the proviral load. c Odds ratio of HAM/TSP conferred by possession of either (CA) 23 or (CA) 24 Cellular immune response to HTLV-1
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In the same study, a multivariate regression was used to identify the significant correlates of proviral load. These results (Vine et al., 2002) showed that, among all the loci tested, the only alleles that exerted a significant influence on the proviral load in healthy carriers were HLA-A*02 and -Cw*08, that is, the two protective class 1 HLA alleles. However, within the patients with HAM/ TSP, the HLA class 1 genotype was not a significant predictor of proviral load. This apparent difference in the control of proviral load between patients with HAM/TSP and healthy carriers suggested either that the CTL response was ineffective in HAM/TSP or that other factors override the influence of CTLs on the proviral load in patients with the disease.
These data (Table 1) give an estimate of the relative risk of HAM/TSP, measured as the odds ratio, in a comparison between HTLV-1-infected individuals in Kagoshima. The data do not give a measure of the influence of host genotype on the absolute risk of HAM/ TSP. Further, the study was designed to answer the question: what is the influence of host genetic polymorphism on the course of HTLV-1 infection? The question whether host genetic polymorphism also influences the risk of acquiring HTLV-1 infection was not addressed in this study, because exposure to HTLV-1 infection occurs by different routes and at different ages; the intensity of exposure by any of these routes is difficult to measure with precision. Owing to these known sources of variation in the intensity of exposure to HTLV-1 infection, it is likely that a large population sample would be required to detect a true effect of host genetics on the risk of acquisition of HTLV-1. However, Plancoulaine et al. (2000) have obtained evidence for such an effect at the level of genetic linkage analysis: it is hoped that the genes responsible can be mapped and identified, to allow a deeper understanding of this interesting and potentially important effect. Rafatpanah et al. (2004) have found a suggestive increase in the frequency of a single-nucleotide polymorphism at nt þ 418 in the perforin gene in patients with HAM/TSP, when compared with uninfected controls. However, there was no significant difference between HAM/TSP patients and asymptomatic carriers of HTLV-1 in the frequency of this polymorphism either at the allele or the genotype level. However, perforin plays a central part in CTL-mediated lysis of virusinfected cells, and Vine et al. (2004) found upregulation of perforin gene expression in subjects with a low proviral load, compared with those with a high load (in two of three experiments; see Figure 1 ). Therefore, it is possible that the þ 418C allele of perforin is associated with more efficient CTL-mediated lysis of HTLV-1-infected cells. Here, the term 'CTL efficiency' refers to the per-CD8 þ cell lytic efficiency as described above (Figure 2a ; Asquith et al., 2005) .
HLA-DR1
The first host gene that was found to influence HTLV-1 infection was HLA-DRB1*0101 (HLA-DR1). Usuku et al. (1990) found that possession of HLA-DR1 was associated with a higher prevalence of HAM/TSP in Japan; this effect was confirmed in subsequent studies (Nishimura et al., 1991; Sonoda et al., 1996; Kitze et al., 1998) . There is recent evidence of a similar susceptibility effect of HLA-DR1 in an HTLV-1-infected population in northern Iran (Sabouri et al., 2005) . Although the effect of HLA-DR1 is somewhat weaker than that of the other polymorphic loci in Kagoshima, in which HLA-DR1 is not a significant independent predictor of the risk of HAM/TSP or proviral load after taking account of the other significant predictors, the reproducibility of the effect at the population level suggests that it is real. However, it is not clear which of several possible mechanisms is responsible for the effect of HLA-DR1 on HTLV-1 infection. This contrasts with the effects of the class 1 HLA genes, where the likely mechanism is straightforward to identify.
Conclusions on the genetic influence on the immune response to HTLV-1
The immunogenetic results obtained to date have corroborated other lines of evidence that variation in the efficiency of HTLV-1-specific CTLs determines variation in the outcome of HTLV-1 infection. The results have also served to identify factors not directly related to the CTL response, which suggest additional mechanisms that influence the outcome of HTLV-1 infection. However, there remains a quantitative disparity between the functional data on the importance of the CD8 þ lymphocyte response (Asquith et al., 2005 ; see above) and the immunogenetic data. That is, the functional data suggest that the variation in the CTL lytic rate accounts for between 30 and 50% of the observed variation in proviral load, whereas the best available genetic model (Vine et al., 2002) accounts for only 5-10% of the observed variation in proviral load. We suggest that other host genetic polymorphisms, still unidentified, are likely to account for the remaining difference between individuals in the proviral load: these polymorphisms may act by determining the efficacy (lytic rate) of HTLV-1-specific CTLs. There are indications that the relative importance of the respective mechanisms of immune surveillance against HTLV-1 might differ quantitatively between populations (Hisada et al., 2004; Sabouri et al., 2005) . As noted above, such differences could be due to variation between the populations in the frequency of certain genetic polymorphisms, particularly HLA alleles, or in the prevalent genotype of HTLV-1. However, it seems unlikely that the fundamental mechanisms will differ qualitatively between populations.
Natural killer (NK) cell response to HTLV-1
The NK cell response to HTLV-1, as in other infections, has been less studied than the antibody and T-cell responses, partly because of the lack of a single surface marker that identifies NK cells in the human, and because of the existence of various lymphocyte subsetssuch as 'NKT' cells -that are intermediate in function and surface marker expression between T cells and 'classical' NK cells.
Evidence was obtained in Japan Yu et al., 1991) that patients with HAM/TSP had both lower frequency and a lower activity of NK cells (especially the CD3 þ CD16 þ subset) than did asymptomatic HTLV-1 carriers, although the results were not normalized with respect to the proviral load.
An important mechanism of induction of NK cellmediated killing is recognition by the NK cell of a complex of the nonpolymorphic MHC molecule HLA-E bound to a peptide derived from HLA-A, -B, or -C molecules (Braud et al., 1998) . Using synthetic tetramers of HLA-E þ peptide to identify NK cells, Saito et al. (2003) found a low frequency of HLA-E tetramerbinding cells in patients with HAM/TSP. Interestingly, as in the earlier studies Yu et al., 1991) , this reduction in frequency was particularly notable in the CD3 þ cells, whereas there was no significant difference in the frequency of HLA-E tetramerbinding CD3
À cells between patients with HAM/TSP and asymptomatic carriers.
The study by Saito et al. (2003) and the earlier work by Yu et al. (1991) and Fujihara et al. (1991) suggested that the activity of the NK or NK-like cell response was associated with the presence or absence of HAM/TSP; the NK frequency and activity did not appear to correlate with proviral load. However, the recent data on lymphocyte gene expression indicated that high levels of expression of certain genes that encode proteins involved in NK cell-mediated lysis were associated with a low proviral load of HTLV-1. These genes, which include NKG2D, NKG2B and NKG2C and NKP46, were highly expressed on CD8 þ cells. In particular, NKG2D was consistently the gene that was most differentially expressed between high-load and low-load subjects. The NKG2D protein serves as a costimulatory molecule on CD8 þ CTLs (Groh et al., 2001) and as a primary recognition receptor on NK cells (Cosman et al., 2001; Pende et al., 2001; Sutherland et al., 2002) . It appears that the cytolytic lymphocyte population that reduces HTLV-1 proviral load contains both 'classical' CD8 þ CTLs and NK or NK-related cells.
Research on the T-cell response to HTLV-1 has focused mainly on the CTL response, because these CTLs are abundant and chronically activated. Indeed, the evidence reviewed above favours the interpretation that CTLs play a major part in controlling the outcome of HTLV-1 infection. The CD4 þ (helper) T-cell response has been more difficult to study, because HTLV-1 Tax protein activates both IFNg transcription and T-cell proliferation, which are the basis of the two most widely used assays of antigen-specific CD4 þ T-cell responses. However, Goon et al. (2002 Goon et al. ( , 2003 Goon et al. ( , 2004a have shown that a short (6-7 h) ELISpot assay can detect antigeninduced cytokine production before the spontaneously expressed Tax protein results in host gene transactivation or T-cell activation. Using this technique, Goon et al. have made three chief observations on the HTLV-1-specific CD4 þ T-cell response. First, the response is dominated by IFNg-producing cells, that is, the potentially pro-inflammatory (Th1) cells (Goon et al., 2002) . Second, the frequency of HTLV-1-specific IFNg producing CD4 þ T cells was between 10 and 25 times greater in HAM/TSP patients than in asymptomatic carriers with a similar proviral load (Goon et al., , 2004a . This difference in T-cell frequency between patients with HAM/TSP and asymptomatic carriers is considerably greater than the two-to four-fold difference observed in the frequency of CTLs between these respective subject groups at a given proviral load. Whatever the cellular dynamics that result in such a high frequency of HTLV-1-specific CD4 þ cells, it seems probable that these cells contribute to the inflammatory tissue damage seen in HAM/TSP, especially since CD4 þ T cells predominate in active (early) inflammatory lesions in this disease (Usuku et al., 1990; Iwasaki et al., 1992) . Finally, Goon et al. (2004b) used the IFNg ELISpot assay to identify the immunodominance hierarchy of HTLV-1 antigens in both the CD4 þ and CD8 þ T-cell response. The results are shown in Table 2 , with the typical range of frequencies of cells of each specificity. The HTLV-1 antigen most commonly recognized by CD4 þ T cells is the Env protein, in contrast with the immunodominance of Tax in the CD8 þ T-cell response. This result is not unusual: glycoproteins frequently predominate as target antigens in the CD4 þ T-cell response to viruses. These results also confirmed the observation of Pique et al. (2000) that a detectable CD8 þ T-cell response is mounted against the regulatory HTLV-1 proteins Tof and Rof.
Pathogenesis of HAM/TSP and other HTLV-1-associated inflammatory diseases
It is widely assumed that the immune response causes the inflammatory tissue damage that is seen in diseases such as HAM/TSP, because the diseases are usually accompanied by high titres of HTLV-1 antibody (Ishihara et al., 1994; Nagai et al., 1998) and high frequencies of activated T cells (Jacobson et al., 1990 (Jacobson et al., , 1992 Elovaara et al., 1993; Greten et al., 1998; Jacobson, 2002) . Also, the tissue damage in the central IFNg ELIspot data taken from Goon et al. (2004a, b) Cellular immune response to HTLV-1 CRM Bangham and M Osame nervous system is associated with dense infiltrates of mononuclear cells, largely T cells (Iwasaki et al., 1992; Iwasaki, 1993) . But how might the immune system actually cause this tissue damage? Broadly, we can identify three possibilities. First, HTLV-1 might itself infect neurons or other resident cells in the central nervous system, and these infected cells could then be attacked by the HTLV-1-specific immune response. This possibility appears to be excluded by the observation that there is little or no HTLV-1 infection of resident cells in the central nervous system in HAM/TSP (Lehky et al., 1995; Matsuoka et al., 1998) . Similarly, in HTLV-1-associated polymyositis, the provirus is present in invading CD4 þ T cells, not in macrophages or myocytes (Higuchi et al., 1996) .
Second, antibodies or T cells that recognize certain HTLV-1 epitopes might crossreact with certain host proteins, a phenomenon known as antigen mimicry. Levin et al. (2002) obtained some intriguing evidence for antigen mimicry in HTLV-1 infection: antibodies that recognize Tax protein can crossreact with a host nuclear riboprotein hnRNP-A1. It is plausible that such autoreactive antibodies might contribute to the tissue damage in an established lesion in HAM/TSP. However, it is unlikely that this mechanism explains the onset or the distribution of the inflammatory lesions, because the host protein hnRNP-A1 is not confined to the central nervous system but is widely expressed, and is not normally accessible to antibody attack.
Finally, the cell damage in the CNS in HAM/TSP might be caused by inflammatory substances released by lymphocytes during the course of an immune response to HTLV-1-infected CD4 þ T cells that have invaded the central nervous system. We suggest that this process, known as 'bystander' or 'collateral' damage, is the most likely pathogenetic mechanism in HAM/TSP (Ijichi et al., 1993; Daenke and Bangham, 1994) . A simple hypothesis of the chain of causes that results in HAM/ TSP can then be suggested: see box 1. Formal tests of the mechanisms of pathogenesis of HAM/TSP are difficult to devise, because of the paucity of animal models of this disease. The prospects of studying the role of the immune response to HTLV-1 in an animal model are perhaps best in the squirrel monkey (Kazanji et al., 1997) or the pig-tailed macaque (McGinn et al., 2004) , but at present there are few appropriate reagents available for experiments in these animals.
Lymphocyte dynamics in HTLV-1 infection
It is now clear that HTLV-1 causes a persistent and highly dynamic infection, with rapid turnover of certain lymphocyte populations. Owing to the dynamic and interconnected nature of the processes involved, including proviral transcription, antigenic stimulation, lymphocyte proliferation and CTL-mediated killing, a full understanding cannot be reached without the use of mathematics (Nowak and Bangham, 1996; Asquith et al., 2002; Asquith and Bangham, 2003) . Even after the molecular details of viral replication and cell-cell interactions are well understood, in order to explain the outcome of infection at the host level, it is necessary to consider the fate of populations of cells, not of individual cells. That is, it is helpful to consider the fate of an individual cell as a balance of probabilities. For example, a CD4 þ T cell in a lymph node that carries the HTLV-1 provirus may be more likely to transcribe HTLV-1 if the cell is stimulated, for example, by antigens or cytokines. Once the cell starts to express Tax protein there is a certain probability (say, p1) that the cell will be stimulated to undergo mitosis, a probability p2 that the cell will be killed by a CTL, and a probability p3 that the cell, activated by Tax protein, crosses the blood vessel endothelium and enters a tissue such as the central nervous system. Not all of these processes are, of course, mutually exclusive. An important challenge in HTLV-1 infection, as in other persistent viral infections, is to identify the critical processes and parameterize themthat is, to estimate the magnitudes of these probabilities or processes -and to identify critical points where these processes can be interrupted.
Conclusions
Variation in the genetically determined efficiency with which an individual's CTLs kill HTLV-1-infected cells appears to be the main cause of variation between hosts in the proviral load of HTLV-1. This efficiency can be measured ex vivo as the rate of lysis of Tax-expressing cells by autologous CTLs. Since the proviral load is strongly correlated with the risk of HAM/TSP, this conclusion implies that CTL lytic efficiency also determines the risk of inflammatory diseases associated with HTLV-1. However, CTL efficiency does not account for all the observed variation in the outcome of HTLV-1 infection; further work is needed to identify the additional factors that result in a higher proviral load in HAM/TSP patients than in asymptomatic carrers at a given level of CTL efficiency (lytic rate).
Patients with HAM/TSP have a 10-to 100-fold greater frequency of HTLV-1-specific CD4 þ T cells than do asymptomatic carriers; this high frequency, which might play a causative role in HAM/TSP, needs explaining. More work is also required to quantify the contribution of NK, NK-related and gd T-cell receptor þ T cells to the control of HTLV-1 infection.
HTLV-1 infection has proved to be a very useful model to understand certain points of principle in persistent viral infections, because both the infected cells and the immune effector cells are accessible and present in high and stable frequencies in the blood, and because the degree of immunosuppression caused by HTLV-1 is small compared with that caused by HIV.
